- Home
- YSG vs FBRX Comparison
YSG vs FBRX Comparison
Compare YSG & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSG | FBRX |
|---|---|---|
| Founded | 2016 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.5M | 487.2M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | YSG | FBRX |
|---|---|---|
| Price | $3.22 | $31.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 144.7K | ★ 384.5K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.87 | $4.91 |
| 52 Week High | $11.04 | $35.80 |
Technical Indicators
Market Signals| Indicator | YSG | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 58.01 |
| Support Level | $2.87 | $26.67 |
| Resistance Level | $4.31 | $31.71 |
| Average True Range (ATR) | 0.18 | 3.33 |
| MACD | 0.05 | 0.70 |
| Stochastic Oscillator | 86.67 | 65.23 |
Price Performance
Historical ComparisonAbout YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.